专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO0159081A2 METHODS FOR USING 20893, A HUMAN PROTEIN KINASE 审中-公开
标题翻译：使用人类蛋白激酶20893的方法
公开(公告)号：WO0159081A2
公开(公告)日：2001-08-16
申请号：PCT/US0104281
申请日：2001-02-09
申请人： MILLENNIUM PHARM INC , GALVIN KATHERINE M , KAPELLER LIBERMANN ROSANA , WEICH NADINE S
发明人： GALVIN KATHERINE M , KAPELLER-LIBERMANN ROSANA , WEICH NADINE S
IPC分类号： A61P1/16 , C12N9/12 , C12N15/54 , A61K38/45 , C07K16/40 , C12N15/11 , C12Q1/68 , G01N33/53
CPC分类号： C12N9/1205
摘要： The present invention relates to methods for using a human protein kinase belonging to the superfamily of mammalian protein kinases. The invention also relates to methods for using polynucleotides encoding the protein kinase. The invention relates to methods using the protein kinase polypeptides and polynucleotides as a target for diagnosis and treatment in protein kinase-mediated or related disorders. The invention further relates to drug-screening methods using the protein kinase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protein kinase polypeptides and polynucletides. The invention further relates to agonists and antagonists identified by drug screening methods with the protein kinase polypeptides and polynucleotides as a target.
摘要翻译：本发明涉及使用属于哺乳动物蛋白激酶超家族的人蛋白激酶的方法。本发明还涉及使用编码蛋白激酶的多核苷酸的方法。本发明涉及使用蛋白激酶多肽和多核苷酸作为蛋白激酶介导的或相关病症中的诊断和治疗靶标的方法。本发明还涉及使用蛋白激酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。本发明还包括基于蛋白激酶多肽和多核苷酸的激动剂和拮抗剂。本发明还涉及通过药物筛选方法鉴定的激动剂和拮抗剂，其中蛋白激酶多肽和多核苷酸作为靶标。

2. 发明申请

WO0224921A3 3700, A NOVEL HUMAN PROTEIN KINASE AND USES THEREFOR 审中-公开
标题翻译： 3700，一种新型人类蛋白激酶及其用途
公开(公告)号：WO0224921A3
公开(公告)日：2003-04-03
申请号：PCT/US0130115
申请日：2001-09-25
申请人： MILLENNIUM PHARM INC , CURTIS RORY A J , GALVIN KATHERINE M
发明人： CURTIS RORY A J , GALVIN KATHERINE M
IPC分类号： C12N9/12 , C12N15/54 , G01N33/50
CPC分类号： C12N9/12 , C07K2319/00
摘要： The invention provides isolated nucleic acids molecules, designated 3700 nucleic acid molecules, which encode a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 3700 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 3700 gene has been introduced or disrupted. The invention still further provides isolated 3700 proteins, fusion proteins, antigenic peptides and anti-3700 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供编码新蛋白激酶的分离的核酸分子，命名为3700个核酸分子。本发明还提供了反义核酸分子，含有3700个核酸分子的重组表达载体，已经引入了表达载体的宿主细胞，以及3700基因被引入或破坏的非人转基因动物。本发明还进一步提供分离的3700蛋白，融合蛋白，抗原肽和抗-3700抗体。还提供了利用本发明组合物的诊断方法。

3. 发明申请

WO2004063340A3 METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE USING 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4 审中-公开
标题翻译：用于治疗心血管疾病的方法和组合物，使用1722,10280,59917,85553,1063,5225,26668,17794,2210,6149,10102,21061,17662,1468,12282,63050,17535,1820,236522,7301,8925， 8701,3533,9462,9123,12788,17729,65552,1261,21476,33770,9380,2569654,33556,5366,44143,32612,10671,261,4457,4
公开(公告)号：WO2004063340A3
公开(公告)日：2005-07-14
申请号：PCT/US2004000393
申请日：2004-01-13
申请人： MILLENNIUM PHARM INC , STAGLIANO NANCY E , HEALY AILEEN , ACTON SUSAN L , GALVIN KATHERINE M , DONOGHUE MARY A , ROGRIGUE-WAY AMELIE , TOMLINSON JAMES E
发明人： STAGLIANO NANCY E , HEALY AILEEN , ACTON SUSAN L , GALVIN KATHERINE M , DONOGHUE MARY A , ROGRIGUE-WAY AMELIE , TOMLINSON JAMES E
IPC分类号： C07K14/47 , G01N33/53 , A61K38/00 , C07K14/00
CPC分类号： C07K14/47
摘要： The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or noncardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
摘要翻译：本发明涉及用于诊断和治疗心血管疾病的方法，包括但不限于动脉粥样硬化，再灌注损伤，高血压，再狭窄，动脉炎症，血栓形成和内皮细胞疾病。具体地说，本发明鉴定了1722,1028,8059917,85553,1063,53235,26668,17794,2210,6169,1010,21061,17662,1468,12282,65050,9035,1820,236522,7301,6005的标准差， 8925,8701,33533,9462,9123,12788,17729,65552,1261,21476,33770,9380,2569654,33556,5366,44143,32612,10677,261,44570,41922,2552,2417,19319,4399， 8921,8993,905,232345,996,1920,17318,1510,14180,26205,554,16408,42028,112091,13886,13942,1673,5496和2419中的基因，相对于它们在正常的表达，心血管疾病状态，或非心血管疾病状态，和/或响应与心血管疾病相关的操作。本发明描述了各种心血管疾病的诊断评估和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。本发明还提供了鉴定能调节心血管疾病的化合物的方法。本发明还提供了用于鉴定和治疗化合物作为心血管疾病治疗的方法。

4. 发明申请

WO2016106357A8 COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS 审中-公开
标题翻译： RAF抑制剂与AURORA激酶抑制剂的组合
公开(公告)号：WO2016106357A8
公开(公告)日：2017-06-01
申请号：PCT/US2015067459
申请日：2015-12-22
申请人： MILLENNIUM PHARM INC
发明人： BOZON VIVIANA , GALVIN KATHERINE M
IPC分类号： A61K9/14
CPC分类号： A61K31/55 , A61K31/506 , A61K45/06 , A61K2300/00
摘要： The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof; the amount of said Raf kinase inhibitor or a pharmaceutically acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.
摘要翻译：本公开涉及用于治疗癌症的方法。具体而言，本公开提供了通过将Raf抑制剂与极光激酶抑制剂组合来治疗癌症的方法。本公开涉及治疗患有癌症的受试者的方法，所述方法包括向所述受试者施用Raf激酶抑制剂或其药学上可接受的盐; 和极光激酶抑制剂或其药学上可接受的盐; 所述Raf激酶抑制剂或其药学上可接受的盐的量使得其组合在治疗癌症中是治疗有效的。在一些实施方案中，癌症是实体肿瘤癌症。

5. 发明申请

WO03033661A8 METHODS OF USING 279, A HUMAN G PROTEIN-COUPLED RECEPTOR 审中-公开
公开(公告)号：WO03033661A8
公开(公告)日：2003-12-24
申请号：PCT/US0232974
申请日：2002-10-16
申请人： MILLENNIUM PHARM INC , LOGAN THOMAS JOSEPH , GALVIN KATHERINE M
发明人： LOGAN THOMAS JOSEPH , GALVIN KATHERINE M
IPC分类号： A61K38/00 , C07K14/705 , C07K14/72 , A61K31/70 , A61K38/16 , A61K38/43 , A61K39/395 , A61K48/00
CPC分类号： C07K14/705 , A61K38/00 , C07K14/723
摘要： The invention provides isolated nucleic acids molecules, designated 279 nucleic acid molecules, which encode human G protein-coupled receptor (GPCR) family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 279 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 279 gene bas been introduced or disrupted. The invention still further provides isolated 279 proteins, fusion proteins, antigenic peptides and anti-279 antibodies. Methods utilizing compositions of the invention to treat, prevent or diagnose angiogenic disorders, e.g., cardiovascular and cancerous disorders, are also provided.

6. 发明申请

WO0164882A9 1983, 52881, 2398, 45449, 50289, AND 52872, G PROTEIN-COUPLED RECEPTORS AND USES THEREFOR 审中-公开
标题翻译： 1983，52881，2398，45449，50289，AND 52872，G蛋白偶联的受体及其用途
公开(公告)号：WO0164882A9
公开(公告)日：2003-01-16
申请号：PCT/US0106543
申请日：2001-02-28
申请人： MILLENNIUM PHARM INC , GLUCKSMANN MARIA ALEXANDRA , GALVIN KATHERINE M , SILOS-SANTIAGO INMACULADA
发明人： GLUCKSMANN MARIA ALEXANDRA , GALVIN KATHERINE M , SILOS-SANTIAGO INMACULADA
IPC分类号： C07K14/705 , C12N15/12 , C12Q1/68 , G01N33/53 , G01N33/68
CPC分类号： C07K14/705
摘要： The invention provides isolated nucleic acids molecules, designated 1983, 52881, 2398, 45449, 50289, and 52872 nucleic acid molecules, which encode G protein-coupled receptor members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 1983, 52881, 2398, 45449, 50289, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 1983, 52881, 2398, 45449, 50289, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 1983, 52881, 2398, 45449, 50289, or 52872 proteins, fusion proteins, antigenic peptides and anti-1983, 52881, 2398, 45449, 50289, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供编码G蛋白偶联受体成员的分离的核酸分子，命名为1983,52881,29898,45449,50289和52872核酸分子。本发明还提供反义核酸分子，含有1983,52881,29898,45449,50289或52872核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中1983,52881 ，2398,45449,50289或52872基因被引入或破坏。本发明还进一步提供了分离的1983,52881,2398,45449,50289或52872蛋白质，融合蛋白质，抗原性肽和抗-1923,52881,2998,45449,50289或52872抗体。还提供了利用本发明组合物的诊断方法。

7. 发明申请

WO03039341A2 METHODS AND COMPOSITIONS TO TREAT CARDIOVASCULAR DISEASE USING 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 OR 93804 审中-公开
标题翻译：使用139,258,1261,1486,2398,2414,7660,85887,10183,10502,12880,17921,32248,60489或93804治疗心血管疾病的方法和组合物
公开(公告)号：WO03039341A2
公开(公告)日：2003-05-15
申请号：PCT/US0235538
申请日：2002-11-05
申请人： MILLENNIUM PHARM INC , LOGAN THOMAS JOSEPH , CHUN MIYOUNG , GALVIN KATHERINE M
发明人： LOGAN THOMAS JOSEPH , CHUN MIYOUNG , GALVIN KATHERINE M
IPC分类号： A61K45/00 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P43/00 , C12N15/09 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/50 , G01N33/566 , G01N33/68 , A61B
CPC分类号： G01N33/502 , C12Q1/6883 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/5008 , G01N33/5067 , G01N33/6893 , G01N2500/00 , G01N2800/32
摘要： The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease. The present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating cardiovascular disease. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease.
摘要翻译：本发明涉及用于诊断和治疗心血管疾病的方法，包括但不限于动脉粥样硬化，再灌注损伤，高血压，再狭窄，动脉炎症，血栓形成和内皮细胞疾病。具体地，本发明鉴定了心血管疾病状态中的139,258,1261,1486,2388,2414,7660,85887,10183,10550,12680,17721,32248,60489或93804基因的差异表达，相对于其在正常或非心血管疾病状态，和/或响应于与心血管疾病相关的操作。本发明描述了各种心血管疾病的诊断评估和预后的方法，以及用于鉴定表现出这种病症倾向的受试者。本发明还提供了鉴定能调节心血管疾病的化合物的方法。本发明还提供了用于鉴定和治疗化合物作为心血管疾病治疗的方法。

8. 发明申请

WO0159081A9 METHODS FOR USING 20893, A HUMAN PROTEIN KINASE 审中-公开
标题翻译：使用20893，人类蛋白激酶的方法
公开(公告)号：WO0159081A9
公开(公告)日：2002-10-31
申请号：PCT/US0104281
申请日：2001-02-09
申请人： MILLENNIUM PHARM INC , GALVIN KATHERINE M , KAPELLER-LIBERMANN ROSANA , WEICH NADINE S
发明人： GALVIN KATHERINE M , KAPELLER-LIBERMANN ROSANA , WEICH NADINE S
IPC分类号： A61P1/16 , C12N9/12 , C12N15/54 , A61K38/45 , C07K16/40 , C12N15/11 , C12Q1/68 , G01N33/53
CPC分类号： C12N9/1205
摘要： The present invention relates to methods for using a human protein kinase belonging to the superfamily of mammalian protein kinases. The invention also relates to methods for using polynucleotides encoding the protein kinase. The invention relates to methods using the protein kinase polypeptides and polynucleotides as a target for diagnosis and treatment in protein kinase-mediated or related disorders. The invention further relates to drug-screening methods using the protein kinase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protein kinase polypeptides and polynucletides. The invention further relates to agonists and antagonists identified by drug screening methods with the protein kinase polypeptides and polynucleotides as a target.
摘要翻译：本发明涉及使用属于哺乳动物蛋白激酶超家族的人蛋白激酶的方法。本发明还涉及使用编码蛋白激酶的多核苷酸的方法。本发明涉及使用蛋白激酶多肽和多核苷酸作为诊断和治疗蛋白激酶介导或相关病症的靶的方法。本发明进一步涉及使用蛋白激酶多肽和多核苷酸鉴定用于诊断和治疗的激动剂和拮抗剂的药物筛选方法。本发明还包括基于蛋白激酶多肽和多核苷酸的激动剂和拮抗剂。本发明进一步涉及以蛋白激酶多肽和多核苷酸作为靶标通过药物筛选方法鉴定的激动剂和拮抗剂。

9. 发明申请

WO0164882A2 1983, 52881, 2398, 45449, 50289, AND 52872, NOVEL G PROTEIN-COUPLED RECEPTORS AND USES THEREFOR 审中-公开
标题翻译： 1983年52881号，2398号，45449号，50289号和52872号，新型G蛋白偶联受体及其用途
公开(公告)号：WO0164882A2
公开(公告)日：2001-09-07
申请号：PCT/US0106543
申请日：2001-02-28
申请人： MILLENNIUM PHARM INC , GLUCKSMANN MARIA ALEXANDRA , GALVIN KATHERINE M , SILOS SANTIAGO INMACULADA
发明人： GLUCKSMANN MARIA ALEXANDRA , GALVIN KATHERINE M , SILOS-SANTIAGO INMACULADA
IPC分类号： C07K14/705 , C12N15/12 , C12Q1/68 , G01N33/53 , G01N33/68
CPC分类号： C07K14/705
摘要： The invention provides isolated nucleic acids molecules, designated 1983, 52881, 2398, 45449, 50289, and 52872 nucleic acid molecules, which encode novel G protein-coupled receptor members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 1983, 52881, 2398, 45449, 50289, or 52872 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 1983, 52881, 2398, 45449, 50289, or 52872 gene has been introduced or disrupted. The invention still further provides isolated 1983, 52881, 2398, 45449, 50289, or 52872 proteins, fusion proteins, antigenic peptides and anti-1983, 52881, 2398, 45449, 50289, or 52872 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供编码新的G蛋白偶联受体成员的分离的核酸分子，命名为1983,52881,29898,45449,50289和52872核酸分子。本发明还提供反义核酸分子，含有1983,52881,29898,45449,50289或52872核酸分子的重组表达载体，已经引入表达载体的宿主细胞，以及非人类转基因动物，其中1983,52881 ，2398,45449,50289或52872基因被引入或破坏。本发明还进一步提供了分离的1983,52881,2398,45449,50289或52872蛋白质，融合蛋白质，抗原性肽和抗-1923,52881,2998,45449,50289或52872抗体。还提供了利用本发明组合物的诊断方法。

10. 发明公开

EP1583966A4 METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE USING 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32 审中-公开
标题翻译：方法和组合物心脏病循环使用1722，10280，59917，85553，10653，9235，21668，17794，2210，6169，10102，21061,17662,1468,12282，6350，9035.1820，23652，7301的治疗， 8925，8701，3533，9462，9123,12788,17729，65552.1261，21476，33770，9380，2569654，33556，53656，44143，32
公开(公告)号：EP1583966A4
公开(公告)日：2007-06-27
申请号：EP04701720
申请日：2004-01-13
申请人： MILLENNIUM PHARM INC
发明人： STAGLIANO NANCY E , HEALY AILEEN , ACTON SUSAN L , GALVIN KATHERINE M , DONOGHUE MARY A , ROGRIGUE-WAY AMELIE , TOMLINSON JAMES E
IPC分类号： C07K14/47 , G01N33/53 , A61K38/00 , C07K14/00
CPC分类号： C07K14/47

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式